


**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:


**Listing of claims:**


1. (currently amended) An  $A_1$ AdoR antagonist that is a 1,3 dipropylxanthine with an ester function at the 8-position, wherein the ester function is a cycloalkyl substituted with  $-\text{COOR}_1$  and wherein  $R_1$  is alkyl, provided that the cycloalkyl is not cyclohexyl when  $R_1$  is methyl.
2. (canceled)
3. (currently amended) The compound, according to claim 1, wherein said ester function has a structure selected from the group consisting of:



and salts thereof; wherein  $R_1$  is alkyl.

4. (currently amended) A pharmaceutical composition comprising an  $A_1$ AdoR antagonist that is a 1,3 dipropylxanthine with an ester function at the 8-position, wherein the ester function is a cycloalkyl substituted with  $-\text{COOR}_1$  and wherein  $R_1$  is alkyl, provided that the cycloalkyl is not cyclohexyl when  $R_1$  is methyl.
5. (canceled)
6. (previously presented) The pharmaceutical composition, according to claim 4, wherein said ester of function has a structure selected from the group consisting of:







and salts thereof; where an  $\text{R}_1$  is alkyl.

7. (currently amended) A method for ~~inhibiting the  $\text{A}_1\text{Ado}$  receptor in an individual in need of diuresis or treatment for treating congestive heart failure in an individual~~ wherein said method comprises administering to said individual effective amount of a pharmaceutical composition comprising an  $\text{A}_1\text{AdoR}$  antagonist that is a 1,3-propylxanthine with an ester function at the 8-position, wherein the ester function is a cycloalkyl substituted with  $\text{-COOR}_1$  and wherein  $\text{R}_1$  is alkyl.

8. (canceled)


9. (currently amended) The method, according to claim 7, wherein said ester function as a structure selected from the group consisting of:






and salts thereof; where an  $R_1$  is alkyl.

10. (original) The method, according to claim 7, wherein the individual is a human.
11. (canceled)
12. (new) An  $A_1$ AdoR antagonist that is a 1,3 dipropylxanthine with an ester function at the 8-position, wherein the ester function has a structure selected from the group consisting of:




and salts thereof; wherein  $R_1$  is alkyl.

13. (new) A pharmaceutical composition comprising an  $A_1$ AdoR antagonist that is a 1,3 dipropylxanthine with an ester function at the 8-position, wherein the ester function has a structure selected from the group consisting of:



and salts thereof; wherein  $R_1$  is alkyl.

14. (new) A method for treating congestive heart failure in an individual wherein said method comprises administering to said individual effective amount of a pharmaceutical composition comprising an  $A_1$ AdoR antagonist that is a 1,3-propylxanthine with an ester function at the 8-position, wherein the ester function has a structure selected from the group consisting of:



and salts thereof; wherein R<sub>1</sub> is alkyl.

15. (new) The method according to claim 14 wherein the individual is a human.